Klein M D, Weiner D A
Circulation. 1987 Jun;75(6 Pt 2):V110-3.
Sustained-release diltiazem (D-SR) and sustained-release verapamil (V-SR) when given twice a day have been successfully used to treat both essential hypertension and angina pectoris. Review of available studies indicates that 120 to 180 mg D-SR twice a day and 240 mg V-SR once or twice a day can lower diastolic pressure in 40% to 80% of patients with essential hypertension and that the drugs may be especially useful in patients with low-renin hypertension such as elderly and black populations. D-SR and V-SR prolong treadmill capacity and reduce frequency of angina in patients with stable effort angina. Improvement is mediated primarily by a reduction in resting and submaximal exercise heart rate. Biopharmaceutics of D-SR and V-SR feature a prolonged apparent plasma half-life and reduced peak-to-trough plasma concentration ratios during steady-state dosing.
缓释地尔硫䓬（D-SR）和缓释维拉帕米（V-SR）每日给药两次已成功用于治疗原发性高血压和心绞痛。对现有研究的回顾表明，每日两次服用120至180毫克D-SR以及每日一次或两次服用240毫克V-SR可使40%至80%的原发性高血压患者的舒张压降低，并且这些药物可能对低肾素性高血压患者（如老年人群和黑人）特别有用。D-SR和V-SR可延长稳定型劳力性心绞痛患者的跑步机运动耐力并减少心绞痛发作频率。改善主要是通过降低静息和次极量运动心率来实现的。D-SR和V-SR的生物药剂学特点是在稳态给药期间表观血浆半衰期延长，峰谷血浆浓度比降低。
